STOCK TITAN
  1. Home
  2. News
  3. SABS

SAB Biotherapeutics Inc - SABS STOCK NEWS

Welcome to our dedicated news page for SAB Biotherapeutics (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SAB Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SAB Biotherapeutics's position in the market.

News
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
Rhea-AI Summary
SAB Biotherapeutics (Nasdaq: SABS) announced the appointment of Katie Ellias to the Company’s Board of Directors. Ms. Ellias, a Managing Director at the JDRF T1D Fund LLC, brings extensive experience in T1D-oriented therapies. With approximately $200 million in assets, the T1D Fund has invested in SAB. Ms. Ellias' expertise and impact are expected to benefit SAB as it aims to change the T1D treatment paradigm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
management
-
News
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
Rhea-AI Summary
SAB Biotherapeutics, Inc. (NASDAQ: SABS) announced the funding of the second tranche of a previously-announced financing, raising total aggregate proceeds to date of $67.1 million. The funds will support the development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditions. Participating investors include Sessa Capital, BVF Partners, RTW Investments, Marshall Wace, ATW, and the JDRF T1D Fund. The investment will move human trials forward for SAB’s lead research program, which was recently granted approval by Australian authorities to begin a first-in-human Phase 1 clinical study of SAB-142.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
-
News
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) has raised a combined $67.1M in a private placement and Tranche warrant exercise with a syndicate of leading investors. The company also received approval from the Human Research Ethics Committee (HREC) to commence a First-in-Human Phase 1 clinical trial investigating SAB-142 in Australia. Additionally, Michael G. King Jr. has been appointed as the new Chief Financial Officer. The company reported financial results for the third quarter of 2023 and provided a company update, highlighting the advancement of SAB-142, their T1D immunotherapy, and the addition of senior expertise to the team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
earnings
News
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
Rhea-AI Summary
SAB Biotherapeutics, Inc. (Nasdaq: SABS) announces CEO's presentation at 35th Annual Piper Sandler Healthcare Conference to discuss the development of hIgG for type 1 diabetes. The event aims to gather industry leaders and investors for trend analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences
-
News
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
Rhea-AI Summary
SAB Biotherapeutics appoints Michael G. King Jr. as Chief Financial Officer. King brings over 25 years of experience as a biotech equity research analyst and senior advisor. He will replace Russell Beyer, who will remain a senior advisor until the end of the year. King's expertise will contribute to SAB's goal of developing disease-modifying treatments for type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
management
-
News
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
Rhea-AI Summary
SAB Biotherapeutics receives approval for Phase 1 clinical study of SAB-142 in Australia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.5%
Tags
clinical trial
News
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
Rhea-AI Summary
SAB Biotherapeutics announces closing of $7.5 million financing and appointment of Andrew Moin to the Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
management
-
News
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
Rhea-AI Summary
SAB Biotherapeutics secures $130 million in funding to support clinical advancement of SAB-142, a potential disease-modifying treatment for type 1 diabetes (T1D)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
-
News
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
Rhea-AI Summary
SAB Biotherapeutics reports Q2 2023 financial results and provides company update. Highlights include positive data for SAB-142 in Type 1 Diabetes and FDA approval for sections of New Animal Drug Application. Cash and cash equivalents at $7.8 million. R&D expenses decrease to $3.7 million. Net loss of $6.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
earnings
News
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
Stock SABS logo
SAB Biotherapeutics Inc

Nasdaq:SABS

SABS Rankings

#4892 Ranked by Market Cap
#1329 Ranked by Stock Gains
N/A Ranked by Dividends

SABS Stock Data

43.13M
5.93M
19.13%
38%
0.31%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Sioux Falls

About SABS

sab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.